Bone metabolism regulators and arterial stiffness in postmenopausal women

Maturitas

Volumn 76, Issue 2, 2013, Pages 146-150

  Albu, A ^a   Fodor, D ^a   Bondor, C ^a   Craciun A M ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Arterial stiffness; Postmenopausal women; Regulators of bone metabolism

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX GLA PROTEIN; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL CALCIFICATION; BONE METABOLISM; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; OSCILLOMETRY; POSTMENOPAUSE; PREDICTOR VARIABLE; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ARTERIAL STIFFNESS; POSTMENOPAUSAL WOMEN; REGULATORS OF BONE METABOLISM;

AGED; BONE AND BONES; CALCIUM-BINDING PROTEINS; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; OSTEOPONTIN; OSTEOPROTEGERIN; PULSE WAVE ANALYSIS; VASCULAR STIFFNESS;

EID: 84888636836     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.07.001     Document Type: Article

References (54)

1. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204(2):321-9.
2. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998;12:1260-8.
3. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-80.
4. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arteriosclerosis, Thrombosis, and Vascular Biology 2001;21:1610-6.
5. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly people. Journal of Clinical Endocrinology and Metabolism 2001;86:631-7.
6. Scatena M, Liaw L, Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2007;27:2302-9.
7. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. Journal of the American Academy of Dermatology 2009;60:225-30.
8. Bazzichi L, Ghiadoni L, Rossi A, et al. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Molecular Medicine 2009;15:402-6.
9. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:333-7.
10. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. Journal of Clinical Investigation 1994;93:2393-402.
11. Vermeer C. Gamma-carboxyglutamate-containing proteins and the vitamin Kdependent carboxylase. Biochemical Journal 1990;266:625-36.
12. O?Donnell CJ, Shea MK, Price PA, et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26:2769-74.
13. Laurent S, Cockroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal 2006;27:2588-605.
14. Mattace-Raso FUS, van der Cammen TJM, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam study. Circulation 2006;113:657-63.
15. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14:373-84.
16. American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care 2010;33(Suppl.):S62-9.
17. US Centers for Disease Control and Prevention. Health behaviors of adults: United States 2005-2007. Vital and Health Statistics 2010;245:80.
18. Baulmann J, Schillings U, Rickert S, et al. A new oscillometric method for assessment of arterial stiffness: Comparison with tonometric and piezo-electric methods. Journal of Hypertension 2008;26:523-8.
19. Jatoi NA, Mahmud A, Bennet K, Feely J. Assessment of arterial stiffness in hypertension: Comparison of oscillometric (Arteriograph), piezoelectric (Complior) and tonometric (SphygmoCor) techniques. Journal of Hypertension 2009;27(21):2186-91.
20. Horvath IG, Nemeth A, Lenkey Z, et al. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. Journal of Hypertension 2010;28(10):2068-75.
21. Hamerman D. Osteoperosis and atherosclerosis: biological linkages and the emergence of dual-propose therapies. Quarterly Journal of Medicine 2005;98:467-84.
22. Nemcsik J, Kiss I, Tisler A. Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease. World Journal of Nephrology 2012;1(1):25-34.
23. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arteriosclerosis, Thrombosis, and Vascular Biology 2000;20:1926-31.
24. Tanko LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. Journal of Bone and Mineral Research 2005;20:1912-20.
25. Doherty TM, Fitzpatrick LA, Inoue D, Qiao J-H, Fishbein MC, Detrano RC. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocrine Reviews 2004;25:629-72.
26. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovascular Research 2005;66:307-17.
27. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: Pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association Writing Group. Circulation 1996;94:1175-92.
28. Zaydun G, Tomiyama H, Hashimoto H, et al. Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase. Atherosclerosis 2006;184:137-42.
29. Takahashi K, Miura S, Mori-Abe A, et al. Impact of menopause on the augmentation of arterial stiffness with aging. Gynecologic and Obstetric Investigation 2005;60:162-6.
30. Sumino H, Ichikawa S, Kasama S, et al. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas 2006;55(3):212-8.
31. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. Journal of the American College of Cardiology 2006;47:1850-7.
32. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. Journal of Biological Chemistry 2001;276: 20659-72.
33. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Research 2004;95:1046-57.
34. Frost ML, Grella R, Millasseau SC, et al. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcified Tissue International 2008;83:112-20.
35. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacology & Therapeutics 2012;135(1):54-70.
36. Toffoli B, Pickering RJ, Tsorotes D, et al. Osteoprotegerin promotes vascular fibrosis via a TGF-1 autocrine loop. Atherosclerosis 2011;218(1):61-8.
37. Lakata EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part III. Cellular and molecular clues to heart and arterial aging. Circulation 2003;107:490-7.
38. Mishima R, Takeshima F, Sawai T, et al. High plasma osteopontin levels in patients with inflammatory bowel disease. Journal of Clinical Gastroenterology 2007;41:167-72.
39. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice. Journal of Experimental Medicine 2002;196:1047-55.
40. Wendelin-Saarenhovi M, Oikonen M, Loo BM, et al. Plasma osteopontin is not associated with vascular markers of subclinical atherosclerosis in a population of young adults without symptoms of cardiovascular disease. The Cardiovascular Risk in Young Finns Study. Scandinavian Journal of Clinical & Laboratory Investigation 2011;71(8):683-9.
41. Lorenzen I, Kramer R, Kliem V, et al. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. European Journal of Clinical Investigation 2010;40:2708-13.
42. Kiefer FW, Zyeda M, Gollinger K, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010;59:935-46.
43. Ste?pień E, Fedak D, Klimeczek P, et al. Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects. Hypertension Research 2012;35:531-8.
44. Barter Ph. Effects of inflammation on high-density lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology 2002;22:1062-3.
45. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arteriosclerosis, Thrombosis, and Vascular Biology 1998;18:1400-7.
46. Braam LA, Dissel P, Gijsbers BL, et al. Assay for human matrix Gla protein in serum: Potential applications in the cardiovascular field. Arteriosclerosis, Thrombosis, and Vascular Biology 2000;20:1257-61.
47. Hermans MM, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, Gladziwa U. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purification 2007;25:395-401.
48. Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrology, Dialysis, Transplantation 2008;23:3263-71.
49. Schurgers LJ, Dissel PE, Spronk HM, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Zeitschrift Fur Kardiologie 2001;90(Suppl. 3):57-63.
50. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005;48:561-8.
51. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. Journal of Clinical Investigation 1993;92:1686-96.
52. Roijers RB, Debernardi N, Cleutjens JP, Schurgers LJ, Mutsaers PH, van der Vusse GJ. Microcalcifications in early intimal lesions of atherosclerotic human coronary arteries. American Journal of Pathology 2011;178:2879-87.
53. Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Current Pharmaceutical Design 2009;15(3):290-303.
54. Dimitrow PP, Jawień M, Gackowski A. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. Journal of Heart Valve Disease 2011;20(1):18-22.